UNSPSC 51142426: Donitriptan hydrochloride

This classification denotes a serotonin agonist with the molecular formula C23H25N5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XTD13T14MR, chemically known as benzonitrile, 4-(4-(2-((3-(2-aminoethyl)-1h-indol-5-yl)oxy)acetyl)-1-piperazinyl)-, hydrochloride (1:1), but more generally known as donitriptan hydrochloride, which bears US NIH Compound Identifier 197705.

European Medicines Agency schedules donitriptan hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01817MIG. Most nations, for tariff purposes, schedule donitriptan hydrochloride under HS 29335995. SMILES: C1CC(CCC1C#N)N2CCN(CC2)C(=O)COC3CCC4C(C3)C(C[NH]4)CCN.CL.

UNSPSC 51142426 Donitriptan hydrochloride is a Commodity code, but the recent state and local opportunities tagged under it do not reflect actual procurement of this specific pharmaceutical product. Instead, the code shows activity related to broader pharmaceutical and drug-supply procurement, including naloxone and generic multi-source pharmaceuticals distributed through state health and cooperative purchasing vehicles. State and local buyers soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope of work centers on purchase and distribution of pharmaceuticals and related products to support public health initiatives, emergency response, and institutional health-care operations, with vendors typically required to maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and contractual relationships with authorized pharmaceutical wholesalers.

Solicitation activity has centered in Florida and Minnesota, with broader multistate reach through cooperative purchasing. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bid, with quarterly deliveries to the county community health building and contract term of two years with one-year renewal option; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and contract effective July 1, 2026; and the Texas Health and Human Services Commission RFI HHS0017013 (posted April 3, 2026) gathering market intelligence on direct-to-manufacturer prescription programs to inform future formal procurement strategy. The mismatch between the code's nominal product (donitriptan hydrochloride, a migraine therapeutic) and the actual procurement activity (emergency-response naloxone, generic pharmaceuticals, and pharmacy benefit programs) suggests the code may be incorrectly applied to these opportunities or reflects broader pharmaceutical sourcing categorization in state procurement systems.